Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Bevacizumab 7.5 and TAC|DRUG: Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)|DRUG: Bevacizumab 15 and TAC|DRUG: Placebo 15 and TAC
Sponsor: Translational Oncology Research International
Collaborators: Genentech, Inc.